drugset / Trial / NCT00841113
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
Timeline
- Start
- 1999-01
- Primary completion
- 2001-02
- Completion
- 2003-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bicalutamide | Other / unclassified | 50 mg | Oral |
| Comparator | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |
| Subject | abarelix | Protein / enzyme biologic | 100 mg | Intramuscular |